Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.42 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27631964 | 0.86 | CHRM2 (0.43) | CHRM2EPHX2PTGS2SLC6A4SLC6A3 | |
| SCHEMBL27616882 | 0.78 | PTGS2 (0.50) | EPHX2PTGS2CYSLTR2CYSLTR1 | |
| SCHEMBL1645197 | 0.77 | PTGS2 (0.49) | EPHX2PTGS2SLC6A4SLC6A3CYSLTR2 | |
| SCHEMBL11751852 | 0.76 | CHRM2 (0.59) | CHRM2SLC6A4SLC6A3BCHEACHE | |
| SCHEMBL9285501 | 0.76 | CHRM2 (0.63) | CHRM2BCHEACHECA12CA2 | |
| SCHEMBL8876620 | 0.76 | PTGS2 (0.51) | EPHX2PTGS2CYSLTR2CYSLTR1 | |
| SCHEMBL1644440 | 0.74 | SLC6A4 (0.49) | PTGS2SLC6A4SLC6A3NPY1R | |
| SCHEMBL27261843 | 0.74 | CYSLTR2 (0.56) | EPHX2PTGS2CYSLTR2CYSLTR1 | |
| SCHEMBL6065023 | 0.74 | CYSLTR2 (0.56) | EPHX2PTGS2CYSLTR2CYSLTR1 | |
| SCHEMBL3016133 | 0.73 | PTGS2 (0.46) | EPHX2PTGS2CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655303-B1 | HYDROGENATION OF ESTERS OR CARBONYL GROUPS WITH TETRADENTATE AMINO/IMINO-THIOETHER BASED RUTHENIUM COMPLEXES | FIRMENICH & CIE (CH) | 2017-02-22 | — | — | EP | claimed |
| EP-2655303-A1 | HYDROGENATION OF ESTERS OR CARBONYL GROUPS WITH TETRADENTATE AMINO/IMINO-THIOETHER BASED RUTHENIUM COMPLEXES | Firmenich SA (CH) | 2013-10-30 | — | — | EP | claimed |
| US-20130274487-A1 | HYDROGENATION OF ESTERS OR CARBONYL GROUPS WITH TETRADENTATE AMINO/IMINO-THIOETHER BASED RUTHENIUM COMPLEXES | FIRMENICH SA (CH) | 2013-10-17 | — | — | US | claimed |
| WO-2012084810-A1 | HYDROGENATION OF ESTERS OR CARBONYL GROUPS WITH TETRADENTATE AMINO/IMINO-THIOETHER BASED RUTHENIUM COMPLEXES | FIRMENICH SA (CH) | 2012-06-28 | — | — | WO | claimed |
| EP-2655303-B1 | HYDROGENATION OF ESTERS OR CARBONYL GROUPS WITH TETRADENTATE AMINO/IMINO-THIOETHER BASED RUTHENIUM COMPLEXES | FIRMENICH & CIE (CH) | 2017-02-22 | — | — | EP | disclosed |
| US-8614345-B2 | Hydrogenation of esters or carbonyl groups with tetradentate amino/imino-thioether based ruthenium complexes | FIRMENICH SA (CH) | 2013-12-24 | — | — | US | disclosed |
| EP-2655303-A1 | HYDROGENATION OF ESTERS OR CARBONYL GROUPS WITH TETRADENTATE AMINO/IMINO-THIOETHER BASED RUTHENIUM COMPLEXES | Firmenich SA (CH) | 2013-10-30 | — | — | EP | disclosed |
| US-20130274487-A1 | HYDROGENATION OF ESTERS OR CARBONYL GROUPS WITH TETRADENTATE AMINO/IMINO-THIOETHER BASED RUTHENIUM COMPLEXES | FIRMENICH SA (CH) | 2013-10-17 | — | — | US | disclosed |
| WO-2012084810-A1 | HYDROGENATION OF ESTERS OR CARBONYL GROUPS WITH TETRADENTATE AMINO/IMINO-THIOETHER BASED RUTHENIUM COMPLEXES | FIRMENICH SA (CH) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274487-A1 | HYDROGENATION OF ESTERS OR CARBONYL GROUPS WITH TETRADENTATE AMINO/IMINO-THIOETHER BASED RUTHENIUM COMPLEXES | ADH5, ADH1A, ADH1C | CHRM2 1898/4885EPHX2 1214/4885PTGS2 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.